Clinical Trial Update: Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus [Phase 1]

View source ↗

Summary

A Phase 1 single-dose study to evaluate the safety, tolerability, and pharmacodynamics of REMD-477 in subjects with Type 1 diabetes mellitus has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus

Drugs mentioned

• REMD-477

Snippet

Sponsor: REMD Biotherapeutics, Inc. | Conditions: Type 1 Diabetes Mellitus, Diabetes | Phase 1 | Status: COMPLETED